Breaking Finance News

A statement released earlier today by Stifel Nicolaus about Puma Biotechnology (NYSE:PBYI) bumps the target price to $88.00

Stifel Nicolaus upped the target price of Puma Biotechnology (NYSE:PBYI) to $88.00 indicating a possible upside of 0.35%.

On 3/29/2016, RBC Capital Markets released a statement for Puma Biotechnology (NYSE:PBYI) bumped down the target price from $103.00 to $36.00 that suggested an upside of 0.02%.

Boasting a price of $65.16, Puma Biotechnology (NYSE:PBYI) traded 3.18% higher on the day. With the last stock price close up 71.03% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Puma Biotechnology has recorded a 50-day average of $56.36 and a two hundred day average of $39.81. Volume of trade was up over the average, with 1,202,068 shares of PBYI changing hands over the typical 840,955

Performance Chart

Puma Biotechnology (NYSE:PBYI)

With a total market value of $0, Puma Biotechnology has with a one year low of $19.74 and a one year high of $94.93 .

A total of 6 equity analysts have released a ratings update on PBYI. Two equity analysts rating the company a strong buy, four equity analysts rating the company a buy, two equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $95.50.

Brief Synopsis About Puma Biotechnology (NYSE:PBYI)

Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the global development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), which the Company is developing for the treatment of patients with human epidermal growth factor receptor type 2 (HER2), positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation; PB272 (neratinib (intravenous)), which the Company is developing for the treatment of patients with advanced cancer, and PB357, which is an orally administered agent. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *